Ionis Pharmaceuticals announced that the European Medicines Agency has accepted the marketing authorization application for review of tofersen, an investigational medicine for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis. SOD1-ALS is a progressive and uniformly fatal disease that affects fewer than 1,000 people across Europe. The FDA has set a PDUFA date for tofersen of April 25, 2023. There are currently no treatments targeted for SOD1-ALS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IONS:
- Ionis Pharmaceuticals, Metagenomi enter gene editing collaboration
- Ionis presents Phase 2 data from open label extension study of donidalorsen
- Ionis Pharmaceuticals backs 2022 revenue above $575M, consensus $594.45M
- Ionis Pharmaceuticals reports Q3 EPS (33c), consensus (74c)
- Ionis Pharmaceuticals announces data from GSK’s Phase 2b study of bepirovirsen